Search

Your search keyword '"Nadal, E."' showing total 151 results

Search Constraints

Start Over You searched for: Author "Nadal, E." Remove constraint Author: "Nadal, E." Database ScienceDirect Remove constraint Database: ScienceDirect
151 results on '"Nadal, E."'

Search Results

2. Molecular profiling and feasibility using a comprehensive hybrid capture panel on a consecutive series of non-small-cell lung cancer patients from a single centre

8. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

9. Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors

20. P3.08E.04 TCR Metrics as Predictive Biomarkers of Response and Survival after Perioperative Chemoimmunotherapy. NADIM & NADIM II Trials

21. P3.08E.01 Perioperative Chemoimmunotherapy Rescue Cold HLA-Deficient Tumors Inducing Strong Immune Responses and Long-Term Survival

28. LBA48 CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)

30. 1284P Clinical utility of liquid biopsy for non-small cell lung cancer patients with ALK fusion variants treated with brigatinib

32. 2MO First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in metastatic non-small cell lung cancer (mNSCLC): Clinical outcomes and biomarker analyses from CheckMate 592

33. A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients

34. VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial

35. 1278P ORIGEN: Multicenter study on the prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain

38. 1509TiP The 1825-EORTC, ALKALINE: Activity of lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with second generation ALK inhibitor

40. 1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A

43. 187P Tissue B-cell receptor repertoire as biomarker of complete pathological response in NSCLC patients treated with neoadjuvant chemoimmunotherapy (NADIM trials)

48. 1630P Effectivity and safety of anti-SARS-CoV2 vaccination in patients with lung cancer: The VAC-CaP observational study (GECP 21/01)

49. 939P Changes in immune gene signatures after neoadjuvant chemoimmunotherapy treatment in NSCLC patients from NADIM trial

Catalog

Books, media, physical & digital resources